Bioventix (LON:BVXP) Reaches New 12-Month Low – Here’s Why

Bioventix PLC (LON:BVXP) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 1,666 and last traded at GBX 1,725, with a volume of 20017 shares changing hands. The stock had previously closed at GBX 1,765.

Bioventix Trading Down 2.3%

The company has a market cap of £90.13 million, a PE ratio of 12.04 and a beta of 0.35. The business has a 50 day simple moving average of GBX 2,130.99 and a two-hundred day simple moving average of GBX 2,442.40.

Bioventix (LON:BVXP) last released its earnings results on Monday, October 27th. The biotechnology company reported GBX 145.27 earnings per share (EPS) for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. On average, equities research analysts expect that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

Insider Activity at Bioventix

In other news, insider Peter John Harrison purchased 875 shares of the stock in a transaction that occurred on Tuesday, November 4th. The stock was acquired at an average cost of GBX 2,220 per share, with a total value of £19,425. Also, insider Bruce Hiscock purchased 150 shares of Bioventix stock in a transaction that occurred on Tuesday, November 25th. The stock was acquired at an average cost of GBX 2,071 per share, with a total value of £3,106.50. In the last ninety days, insiders have purchased 1,644 shares of company stock worth $3,424,721. 6.16% of the stock is currently owned by company insiders.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.